{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:05:01Z","timestamp":1779433501655,"version":"3.53.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>C3 glomerulopathy (C3G) and primary (idiopathic) immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare progressive kidney diseases. Due to the rare nature of C3G\/primary IC-MPGN, there is a paucity of real-world data on the diagnosis, management, and impact of the diseases on patients and caregivers. Our study used the direct experiences of healthcare professionals (HCPs), patients, and caregivers, to provide insight into the diagnosis\/management of C3G\/primary IC-MPGN and its burden on patients and caregivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multi-country, cross-sectional, semi-structured, qualitative interview study with HCPs, patients, and caregivers in France, Germany, Italy, Spain, the United Kingdom and the United States between July 2024\u2212January 2025. Nephrologists or internal medicine specialists (France and Spain only) were eligible to participate if they managed at least one patient with a biopsy-confirmed C3G\/primary IC-MPGN diagnosis. Patients and informal caregivers were recruited via HCPs, patient advocacy groups, online panels or social media and had to be aged \u226516 years and \u226518 years respectively. Thematic analysis was conducted to identify key response themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 HCPs, 13 patients, and 8 caregivers were interviewed. HCPs and patients highlighted that milder symptoms often led to diagnostic delays with HCPs highlighting lack of disease recognition, difficulties accessing specialist care, and patient reluctance to receive a biopsy as barriers to timely diagnosis. Mental and physical fatigue\/exhaustion were the most burdensome symptoms according to patients and caregivers, impacting all aspects of the patient\u2019s life. Patients stated that achieving disease stability was a key goal of treatment, however HCPs, patients, and caregivers all stated that treatment options at survey (prior to approval of iptacopan and pegcetacoplan) were limited, with dialysis being particularly burdensome to patients. HCPs were hopeful about future treatment options. Caregivers reported that they provided physical and psychological support and advocated for their patient. Caregiving had a substantial impact on the caregiver\u2019s mental wellbeing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, C3G\/primary IC-MPGN presented a substantial burden to patients and caregivers, with a need for timely diagnosis, psychological support for patients and caregivers, improved HCP-patient communication, and treatments which target the cause of C3G\/primary IC-MPGN to stabilize the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneph.2026.1770706","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:08:46Z","timestamp":1779430126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["\u2018\u2026completely exhausted and weak, really drained.\u2019: a multinational qualitative interview study of healthcare provider, patient, and caregiver experiences of C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis diagnosis, burden and management"],"prefix":"10.3389","volume":"6","author":[{"given":"Sayna","family":"Norouzi","sequence":"first","affiliation":[{"name":"Division of Nephrology, Loma Linda University Medical Center","place":["Loma Linda, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Huang","sequence":"additional","affiliation":[{"name":"Apellis Pharmaceuticals, Inc.","place":["Waltham, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Rich","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Gordon","sequence":"additional","affiliation":[{"name":"Apellis Pharmaceuticals, Inc.","place":["Waltham, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Quintana-Gallardo","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Naylor","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Amet","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mirams","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Holdsworth","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"B1","unstructured":"Prevalence of rare diseases: Bibliographic data: Orphanet Report Series, Rare Diseases collection. Diseases listed in alphabetical order\n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy\u2014understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000507254","article-title":"Update on C3 glomerulopathy: A complement-mediated disease","volume":"144","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Nephron"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050712","article-title":"Diagnostic and prognostic comparison of immune-complex-mediated membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"12","author":"Kovala","year":"2023","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2215\/cjn.16801221","article-title":"Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis","volume":"17","author":"Lomax-Browne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.01.024","article-title":"Comparative analysis of proteinuria and longitudinal outcomes in immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"10","author":"Caravaca-Font\u00e1n","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000474","article-title":"C3 glomerulopathy recurs early after kidney transplantation in serial biopsies performed within the first 2 years after transplantation","volume":"19","author":"Tarrag\u00f3n","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab281","article-title":"Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment","volume":"38","author":"Noris","year":"2023","journal-title":"Nephrol Dialysis Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2019040433","article-title":"Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy","volume":"31","author":"Levine","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ekir.2023.10.022","article-title":"Iptacopan in idiopathic immune complex\u2013mediated membranoproliferative glomerulonephritis: Protocol of the APPARENT multicenter, randomized phase 3 study","volume":"9","author":"Vivarelli","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ekir.2024.09.017","article-title":"Challenges in the diagnosis and management of immune complex-mediated membranoproliferative glomerulonephritis and complement 3 glomerulopathy","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cvr\/cvab287","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Conference","year":"2021","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Garabed Eknoyan","year":"2021","journal-title":"Kidney Int"},{"key":"B17","volume-title":"Novartis receives third FDA approval for oral Fabhalta\u00ae (iptacopan) \u2013 the first and only treatment approved in C3 glomerulopathy (C3G)","year":""},{"key":"B18","article-title":"FDA","volume-title":"Approves Apellis\u2019 EMPAVELI\u00ae (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older","year":""},{"key":"B19","unstructured":"Fabhalta"},{"key":"B20","unstructured":"Aspaveli"},{"key":"B21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00467-020-04736-8","article-title":"Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis","volume":"36","author":"Khandelwal","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.09.019","article-title":"Long-term outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children","volume":"5","author":"Kirpalani","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000547744","article-title":"Treatment and disease burden in patients with complement 3 glomerulopathy: multinational real-world study results","volume":"5","author":"Sinha","year":"2025","journal-title":"Glomerular Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000548245","article-title":"Clinical presentation, treatment patterns, burden of disease, and the association of proteinuria with clinical outcomes in C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis: A systematic review","volume":"150","author":"Caravaca-Font\u00e1n","year":"2026","journal-title":"Nephron"},{"key":"B26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1053\/j.ajkd.2019.05.025","article-title":"Patient-reported outcome measures for adults with kidney disease: current measures, ongoing initiatives, and future opportunities for incorporation into patient-centered kidney care","volume":"74","author":"Nair","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179733","article-title":"Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: A systematic review","volume":"12","author":"Aiyegbusi","year":"2017","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.17309\/jltm.2024.5.3.09","article-title":"Implications and critiques of quantitative research: A systematic review","volume":"5","author":"Sapkota","year":"2024","journal-title":"J Learn Theory Method"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13888","article-title":"Qualitative research methods and its application in nephrology","volume":"26","author":"Guha","year":"2021","journal-title":"Nephrology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.jval.2024.10.314","article-title":"EE30 real-world survey on healthcare resource utilization and physician-reported burden in patients with primary immune complex membranoproliferative glomerulonephritis","volume":"27","author":"Rich","year":"2024","journal-title":"Value Health"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100808","article-title":"Educational needs in diagnosing rare diseases: A multinational, multispecialty clinician survey","volume":"1","author":"Rohani-Montez","year":"2023","journal-title":"Genet Med Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad182","article-title":"C3G and ig-MPGN-treatment standard","volume":"39","author":"Noris","year":"2024","journal-title":"Nephrol Dialysis Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.01.033","article-title":"Are your kidneys ok? Detect early to protect kidney health","volume":"10","author":"Vassalotti","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000334","article-title":"Participant experience with protocol research kidney biopsies in the Kidney Precision Medicine Project","volume":"19","author":"Victoria-Castro","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2023.07.028","article-title":"Now or later? Patient satisfaction and anxiety among women undergoing breast biopsies performed the same day as recommended versus a later day","volume":"21","author":"Grimm","year":"2024","journal-title":"J Am Coll Radiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/ijerph19020783","article-title":"The effect of an informative video upon anxiety and stress in patients requiring an oral biopsy: A randomized controlled study","volume":"19","author":"Toralla","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310358","article-title":"\u2018Was my kidney biopsy worth it?\u2019\u2013A qualitative phenomenological study of patient experiences and perceived barriers to kidney biopsy","volume":"19","author":"Toal","year":"2024","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051227","article-title":"Quality improvement initiatives in renal biopsy for patient-centered communication by shared decision making","volume":"12","author":"Chen","year":"2022","journal-title":"Diagnostics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100928","article-title":"Establishing the future direction of clinical outcomes in C3 glomerulopathy: Perspectives from a patient and a physician","volume":"7","author":"Java","year":"2025","journal-title":"Kidney Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.19891220","article-title":"Fatigue in CKD: Epidemiology, pathophysiology, and treatment","volume":"16","author":"Gregg","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.1313","article-title":"#2632 quality of life and fatigue burden in individuals living with complement 3 glomerulopathy \u2013 a real-world study","volume":"39","author":"Lafayette","year":"2024","journal-title":"Nephrol Dialysis Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf118","article-title":"Fatigue across different chronic kidney disease populations: experiences and needs of patients","volume":"18","author":"SChade van Westrum","year":"2025","journal-title":"Clin Kidney J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.37526\/1526-744x.2025.52.4.411","article-title":"Shared decision-making and quality of life in patients with chronic kidney disease: A systematic review","volume":"52","author":"Kim","year":"2025","journal-title":"Nephrol Nurs J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.52225\/narra.v3i3.215","article-title":"Psychological impact of chronic kidney disease and hemodialysis: Narrative review","volume":"4","author":"Alkhaqani","year":"2022","journal-title":"Psychosomatic Med Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.338306","article-title":"Quality of life of patients with chronic kidney disease: A comparative study between nondialysis and dialysis patients","volume":"32","author":"Almutary","year":"2021","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.09.028","article-title":"Health-related quality of life in people across the spectrum of CKD","volume":"5","author":"Krishnan","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2020.109995","article-title":"Symptom dimensions of anxiety and their association with mortality, hospitalization and quality of life in dialysis patients","volume":"133","author":"Schouten","year":"2020","journal-title":"J Psychosomatic Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2023.1281878","article-title":"Anxiety and depression in geriatric hemodialysis patients: factors that influence the border of diseases","volume":"14","author":"Elezi","year":"2023","journal-title":"Front Psychol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/medicina55050168","article-title":"Anxiety-depression of dialysis patients and their caregivers","volume":"55","author":"Gerogianni","year":"2019","journal-title":"Med (Kaunas)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2024-001953","article-title":"Initiatives to enhance referral patterns from primary care to specialist kidney care: a systematic review and meta-analysis","volume":"3","author":"Ghimire","year":"2025","journal-title":"BMJ Public Health"},{"key":"B52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ekir.2025.10.020","article-title":"Current and emerging therapies for C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis","volume":"11","author":"Kavanagh","year":"2026","journal-title":"Kidney Int Reports\u00ae"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00476-9","article-title":"Clinical and humanistic burden of IgA nephropathy in adult patients: a global real-world survey","volume":"6","author":"Tang","year":"2025","journal-title":"Kidney360"},{"key":"B54","doi-asserted-by":"publisher","first-page":"19595","DOI":"10.1038\/s41598-019-56102-w","article-title":"Association between health related quality of life and progression of chronic kidney disease","volume":"9","author":"Oh","year":"2019","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17437199.2017.1298045","article-title":"Examining the efficacy of social-psychological interventions for the management of fatigue in end-stage kidney disease (ESKD): a systematic review with meta-analysis","volume":"11","author":"Picariello","year":"2017","journal-title":"Health Psychol Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822x05279903","article-title":"How many interviews are enough? An experiment with data saturation and variability","volume":"18","author":"Guest","year":"2006","journal-title":"Field Methods"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: a systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1770706\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:08:48Z","timestamp":1779430128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1770706\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":57,"alternative-id":["10.3389\/fneph.2026.1770706"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1770706","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1770706"}}